Effects of modification of the active site tyrosine of human DNA topoisomerase I.
The human topoisomerase I-mediated DNA relaxation reaction was studied following modification of the enzyme at the active site tyrosine (position 723). A series of unnatural tyrosine analogues was incorporated into the active site of human topoisomerase I by utilizing misacylated suppressor tRNAs in an in vitro protein synthesizing system. The relaxation activities of the modified human topoisomerase I analogues having varied steric, electronic, and stereochemical features were all greatly diminished relative to that of the wild type. It was found that modifications involving replacement of the nucleophilic tyrosine OH group with NH2, SH, or I groups eliminated DNA relaxation activity, as did changing the orientation of the nucleophilic tyrosine OH group. Only tyrosine analogues having the phenolic OH group in the normal position with respect to the protein backbone were active; the relative activities could be rationalized in chemical terms on the basis of the H-bonding and the electronic effects of the substituents attached to the meta position of the aromatic ring. In addition, the poisoning of one of the modified human topoisomerase I analogues, as part of covalent binary complexes with DNA, by CPT and 20-thio CPT was evaluated.
Gao
Rong
R
Department of Chemistry, University of Virginia, Charlottesville, Virginia 22901, USA.
Zhang
Yi
Y
Dedkova
Larisa
L
Choudhury
Ambar K
AK
Rahier
Nicolas J
NJ
Hecht
Sidney M
SM
D001665:Binding Sites; D002166:Camptothecin / Q000494:pharmacology; D004264:DNA Topoisomerases, Type I / Q000737:chemistry*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D059004:Topoisomerase I Inhibitors; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000737:chemistry*
D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D014443:Tyrosine; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin